

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". The complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



Section 1.	Identifying Information									
1. Given Name (Fii Brian	rst Name)	2. Surname (Last Name) Feagan		3. Effective Date (07-August-2008) 01-October-2014						
4. Are you the corresponding author?		Yes 🖌 No	Corresponding Author's Na	me						
5. Manuscript Title 2014-2015 ECCO		Potential Conflicts of Inter	est							
6. Manuscript Ider	ntifying Number (if you l	know it)								

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

The Work Under Consideration for Publication								
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**			
1. Grant	\checkmark					×		
						ADD		
2. Consulting fee or honorarium	\checkmark					×		
						ADD		
3. Support for travel to meetings for the study or other purposes	\checkmark					×		
						ADD		
 Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like 	✓					×		
						ADD		
Payment for writing or reviewing the manuscript	\checkmark					×		
						ADD		
 Provision of writing assistance, medicines, equipment, or administrative support 	\checkmark					×		



The Work Under Consideration for Publication									
Туре	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**				
						ADD			
7. Other	\checkmark					×			
						ADD			

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.

Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership		\checkmark		Abbott		×		
1. Board membership		\checkmark		Astra Zeneca		×		
1. Board membership		\checkmark		Amgen		×		
1. Board membership		\checkmark		Celgene		×		
1. Board membership		\checkmark		Centacor		×		
1. Board membership		\checkmark		Merck		×		
1. Board membership		\checkmark		Novartis		×		
1. Board membership		\checkmark		Pfizer		×		
1. Board membership		\checkmark		Prometheus Laboratories		×		
1. Board membership		\checkmark		Salix Pharma		×		
1. Board membership		\checkmark		Takeda		×		
1. Board membership		\checkmark		Tillotts Pharma AG		×		
1. Board membership		\checkmark		UCB Pharma		×		



Relevant financial activities outside the submitted work								
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments			
1. Board membership		\checkmark		Avaxia Biologics Inc		×		
1. Board membership		\checkmark		Bristol-Myers Squibb		×		
1. Board membership		\checkmark		Centocor		×		
1. Board membership		\checkmark		Elan/Biogen		×		
1. Board membership		\checkmark		Ferring		×		
1. Board membership		\checkmark		JnJ/Janssen		×		
1. Board membership		\checkmark		Novo Nordisk		×		
1. Board membership		\checkmark		Protagonist		×		
1. Board membership		\checkmark		Teva		×		
1. Board membership		\checkmark		TiGenix		×		
						ADD		
2. Consultancy		\checkmark		Abbott (AbbVie)		×		
2. Consultancy		\checkmark		ActoGeniX		×		
2. Consultancy		\checkmark		Albireo Pharma		×		
2. Consultancy		\checkmark		Amgen		×		
2. Consultancy		\checkmark		Astra Zeneca		×		
2. Consultancy		\checkmark		Avaxia Biologics Inc		×		
2. Consultancy		\checkmark		Axcan		×		
2. Consultancy		\checkmark		Boehringer-Ingelheim France		×		
2. Consultancy		\checkmark		Bristol-Myers Squibb		×		
2. Consultancy		\checkmark		Celgene		×		
2. Consultancy		\checkmark		Centocor		×		
2. Consultancy		\checkmark		Elan/Biogen		×		
2. Consultancy		\checkmark		Ferring Pharma A/S		×		
2. Consultancy		\checkmark		Genentech		×		
2. Consultancy		\checkmark		GiCare Pharma		×		
2. Consultancy		\checkmark		Gilead		×		
2. Consultancy		\checkmark		Given Imaging Inc		×		



2. Consultancy	\checkmark	GSK	×
2. Consultancy	\checkmark	Ironwood Pharma	×
2. Consultancy	\checkmark	Johnson & Johnson/ Janssen	×
2. Consultancy	\checkmark	Merck	×
2. Consultancy	\checkmark	Millennium	×
2. Consultancy	\checkmark	Nektar	×
2. Consultancy	\checkmark	NovoNordisk	×
2. Consultancy	\checkmark	Prometheus Therapeutics & Diagnostics	×
2. Consultancy	\checkmark	Pfizer	×
2. Consultancy	\checkmark	Salix Pharma	×
2. Consultancy	\checkmark	Serono	×
2. Consultancy	\checkmark	Shire	×
2. Consultancy	\checkmark	Sigmoid Pharma	×
2. Consultancy	\checkmark	Synergy Pharma Inc	×
2. Consultancy	\checkmark	Takeda	×
2. Consultancy	\checkmark	TEVA Pharma	×
2. Consultancy	\checkmark	Tillotts	×
2. Consultancy	\checkmark	UCB Pharma	×
2. Consultancy	\checkmark	Warner-Chilcott	×
2. Consultancy	\checkmark	Wyeth	×
2. Consultancy	\checkmark	Zealand Pharma	×
2. Consultancy	\checkmark	Zyngenia	×
2. Consultancy	\checkmark	Atlantic Pharma	×
2. Consultancy	\checkmark	Avir Pharma	×
2. Consultancy	\checkmark	Baxter Healthcare Corp	×
2. Consultancy	\checkmark	Calypso Biotech	×
2. Consultancy	\checkmark	EnGene	×
2. Consultancy	\checkmark	Kyowa Kakko Kirin	×
2. Consultancy	\checkmark	Lexicon	×
2. Consultancy	\checkmark	Lilly	×



2. Consultancy		\checkmark		Protagonist	×
2. Consultancy		\checkmark		Receptos	×
2. Consultancy		\checkmark		TiGenix	×
2. Consultancy		\checkmark		Vertex	×
					ADD
3. Employment	\checkmark				×
					ADD
4. Expert testimony	\checkmark				×
					ADD
5. Grants/grants pending			\checkmark	Abbott/AbbVie	×
5. Grants/grants pending			\checkmark	Amgen	×
5. Grants/grants pending			\checkmark	Astra Zeneca	×
5. Grants/grants pending			\checkmark	Bristol-Myers Squibb	×
5. Grants/grants pending			\checkmark	Janssen Biotech	×
5. Grants/grants pending			\checkmark	La Roche/Genentech	×
5. Grants/grants pending			\checkmark	Millennium	×
5. Grants/grants pending			\checkmark	Pfizer	×
5. Grants/grants pending			\checkmark	Receptos	×
5. Grants/grants pending			\checkmark	Santarus	×
5. Grants/grants pending			\checkmark	Sanofi	×
5. Grants/grants pending			\checkmark	Takeda	×
5. Grants/grants pending			\checkmark	Tillotts	×
5. Grants/grants pending			\checkmark	UCB	×
					ADD
Payment for lectures including service on speakers bureaus		\checkmark		Johnson & Johnson/ Janssen	×
Payment for lectures including service on speakers bureaus		\checkmark		Abbott Labs	×
Payment for lectures including service on speakers bureaus		\checkmark		UCB	×
Payment for lectures including service on speakers bureaus		\checkmark		Takeda	×
					ADD



7. Payment for manuscript preparation	\checkmark			×
				ADD
 Patents (planned, pending or issued) 	\checkmark			×
				ADD
9. Royalties	\checkmark			×
				ADD
10. Payment for development of educational presentations	\checkmark			×
				ADD
11. Stock/stock options	\checkmark			×
				ADD
 Travel/accommodations/ meeting expenses unrelated to activities listed** 	\checkmark			×
				ADD
13. Other (err on the side of full disclosure)	\checkmark			×
				ADD

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.